Eyepoint Pharmaceuticals (NASDAQ:EYPT) Research Coverage Started at Stifel Nicolaus

Stifel Nicolaus assumed coverage on shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT) in a report published on Thursday, MarketBeat reports. The firm issued a buy rating and a $40.00 price target on the stock.

Other analysts also recently issued research reports about the stock. Royal Bank Of Canada cut their price target on shares of Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Guggenheim reissued a “buy” rating and issued a $68.00 price objective on shares of Eyepoint Pharmaceuticals in a research note on Wednesday, June 24th. Chardan Capital boosted their price objective on shares of Eyepoint Pharmaceuticals from $29.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. Cantor Fitzgerald assumed coverage on Eyepoint Pharmaceuticals in a research note on Wednesday, July 8th. They set an “overweight” rating and a $47.00 target price for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $43.75.

Eyepoint Pharmaceuticals Stock Up 2.0%

EYPT stock opened at $13.30 on Thursday. Eyepoint Pharmaceuticals has a 52 week low of $9.40 and a 52 week high of $19.11. The business has a 50-day simple moving average of $13.26 and a 200 day simple moving average of $14.24. The company has a market cap of $1.12 billion, a PE ratio of -3.80 and a beta of 1.73.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.20). Eyepoint Pharmaceuticals had a negative return on equity of 110.54% and a negative net margin of 3,566.63%.The firm had revenue of $0.70 million for the quarter, compared to analyst estimates of $0.35 million. On average, analysts anticipate that Eyepoint Pharmaceuticals will post -3.31 EPS for the current fiscal year.

Hedge Funds Weigh In On Eyepoint Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in EYPT. KBC Group NV acquired a new stake in Eyepoint Pharmaceuticals in the first quarter valued at approximately $29,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Eyepoint Pharmaceuticals by 51.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company’s stock worth $74,000 after buying an additional 1,358 shares in the last quarter. California State Teachers Retirement System increased its holdings in shares of Eyepoint Pharmaceuticals by 20.6% during the fourth quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock worth $85,000 after buying an additional 794 shares in the last quarter. Russell Investments Group Ltd. bought a new position in shares of Eyepoint Pharmaceuticals in the 3rd quarter valued at $76,000. Finally, Persistent Asset Partners Ltd bought a new position in shares of Eyepoint Pharmaceuticals in the 4th quarter valued at $98,000. Institutional investors own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.